Connect with us

Hi, what are you looking for?

Saturday, Jun 15, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Zelira launches new fast acting capsule and tablet technology

Company claims its innovative patented tech will accelerate dissolution rates of distillate when administered orally

Zelira launches new capsule and tablet technology
Photo via Zelira Therapeutics.

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) has now invented a new technology that it says will be a valuable tool for cannabinoid producers around the globe.

On Tuesday, the Australian medical cannabinoid company announced the launch of ZYRAYDI, a proprietary enhanced distillate capture and dissolution matrix (EDCDM) technology.

The company claims that ZYRAYDI enables it to trap distillate in a so-called “free flow powder matrix” therefore enabling increased rates of dissolution in the body.

Read more: Kiva launches market donation program to prevent cannabis waste

Read more: Cannara Biotech enters British Columbia market, launches first live resin vape

The company says that using ZYRAYDI will only require minimal capital expenditure on raw materials and equipment and that it can easily adapt to any pre-existing capsule and tablet program from other companies.

Zelira says that the matrix for the new technology consists of pharmaceutical grade excipients that are approved by the FDA and can be altered to cater to vegan, allergen free, non-GMO and other requirements depending on who chooses to utilize it.

“ZYRAYDI solves two key issues holding back wider acceptance of cannabinoid medicinal products – the difficulty in formulating solid oral dosage drugs with distillate, and the low rate of dissolution in the body from capsules and tablets,” said Oludare Odumosu, CEO of Zelira Therapeutics.

“We strongly believe that the cannabinoid-based medicine market will scale up significantly when the ability to consistently formulate, validate and commercialize dosage forms that closely resemble current pharmaceutical drugs becomes available,” added Odumosu in relation to the potential of ZYRAYDI.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook







Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The Science of Smokeability study will be ongoing for the next two years


The 2024 amendment will jeopardize the multi-billion dollar hemp industry


Although both compounds are found in the cannabis plant, there are significant differences in their effects and legislation


The Justice Department confirms that the DEA (Drug Enforcement Agency) is moving to reclassify cannabis